Aridis Pharmaceuticals, Inc.

34 articles with Aridis Pharmaceuticals, Inc.

• Aridis Pharmaceuticals Announces First Quarter 2019 Results

  5/14/2019

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2019.

• Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update

  3/28/2019

  The Company, which is utilizing its proprietary MabIgX® antibody discovery platform to develop novel therapies for hospital acquired infections made considerable clinical development advances with its lead monoclonal antibody programs, AR-301 and AR-105, along with its cystic fibrosis (CF) candidate AR-501, an inhalable therapy to treat chronic lung infections impacting CF patients.

• AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients

  12/12/2018

  Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer

• Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

  12/4/2018

  CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million

• Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview

  11/13/2018

  Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market

• Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"

  11/7/2018

  Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine

• 

  Aridis Pharma Deepens Patents for Infectious Disease Therapies

  9/24/2018

  Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.

• Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates

  9/24/2018

  New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio

• Aridis Pharmaceuticals Announces Pricing of Initial Public Offering

  8/14/2018

  Aridis Pharmaceuticals, Inc. announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million

• Aridis Pharmaceuticals Launches Proposed Initial Public Offering

  8/6/2018

  Aridis Pharmaceuticals, Inc. today announced that it has launched an initial public offering of 2,000,000 shares of its common stock.

• Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its Monoclonal Antibody Therapies in China

  2/27/2018

  Aridis Pharmaceuticals, Inc. today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China's leading pharmaceutical companies.

• T2 Biosystems And Aridis Pharma Join Antimicrobials Working Group

  8/15/2017

• Aridis Pharma Appoints Alan H. Cohen, MD, As Senior Vice President Of Clinical & Medical Affairs

  8/7/2017

• Aridis Pharma Enrolls First Patients In Global Pivotal Clinical Trial Of Novel Monoclonal Antibody For Treating Acute Pneumonia

  8/2/2017

• Aridis Pharma Presents Positive Phase IIa Safety And Efficacy Data Of Salvecin (AR-301) In Patients With Severe Pneumonia Caused By Staphylococcus Aureus During The 2017 ASM Microbe Congress

  6/5/2017

• Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia

  1/6/2017

• Aridis Pharmaceuticals Expands The Company's Clinical Advisory Board; Adds Three Industry Veterans With Unique Expertise In The Field

  7/11/2016

• Aridis Pharmaceuticals Strengthens Board Of Directors With Former Wyeth (Now Pfizer President Of R&D Robert Ruffolo, Jr.

  4/18/2016

• Aridis Pharmaceuticals Expands Patent Portfolio For Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets

  2/24/2016

• Aridis Pharmaceuticals To Present At BIO CEO & Investor Conference 2016

  2/2/2016